

Aim: Utilize standard risk stratification to guide efficient and effective work-up of possible appendicitis.

ED Note 1: Classic Features

- Pain <36 hours duration
- History of focal RLQ pain
- History of migration of pain
- Focal tenderness in RLQ
- Pain with walking/jumping or coughing

*If appendicitis is confirmed:

- Refer to [Appendicitis Inpatient/Surgical Guideline](#) (page 2-5)
- Consult General Surgery, Hospitalist if suspected perforation OR night admit ([page 5](#))
- Keep NPO (Clear liquids if admitted after hours, must be NPO by 0000), IV fluids, symptom management
- Once diagnosis confirmed, initiate antibiotics while awaiting surgical intervention ([page 2](#))

Patient presents to the ED with abdominal pain

Clinical concern for appendicitis

(ED Note 1)

Initial management:

- NPO
- IV access
- Symptom management

Lab evaluation:**

- CBC w/ diff
- Urine analysis
- Urine pregnancy (if post-pubertal female)

ED Note 2: pARC Score Clinical Considerations

- Duration of pain
- Abdominal pain migrates to RLQ
- Pain with walking/jumping or coughing
- Right-sided abdominal tenderness
- Maximal tenderness in RLQ
- Involuntary/voluntary abdominal guarding
- White Blood Cell count (WBC)
- Percent neutrophils
- Absolute neutrophil count (ANC)

Enter this data into: mdcalc.com/calc/10201/pediatric-appendicitis-risk-calculator-parc

****Blood cultures** are not routinely indicated when concerned for appendicitis. Only obtain a blood culture if there is clinical concern for sepsis or bacteremia.

Predicted Risk of Appendicitis

Use pARC Score
(ED Note 2)

High

Predicted risk >85%

SUGGESTED MANAGEMENT*

For patients *without* uterus/ovaries:
Begin with surgical consult. Obtain diagnostic imaging as per surgeon's recommendation.

For patients *with* uterus/ovaries:
Begin with abdominal/pelvic ultrasound. Consult surgery. If ultrasound is equivocal, consider CT with IV contrast.

Intermediate

Predicted risk 50–84%

SUGGESTED MANAGEMENT*

Begin with abdominal/pelvic ultrasound to rule out appendicitis. If ultrasound is equivocal, consider CT with IV contrast or admission to inpatient for observation.

Predicted risk 11–49%

SUGGESTED MANAGEMENT* Clinical discretion and family preference

- Perform an abdominal/pelvic ultrasound to rule out appendicitis **OR**
- Observe in the ED for 4–6 hours **OR**
- Admit to short stay for serial exams **OR**
- If risk is between 10–25%, and if family and PCP are agreeable and there are no barriers, such as transportation, follow-up next day may be considered.

Low

Predicted risk <10%

SUGGESTED MANAGEMENT


Patients in this category are at low risk for appendicitis - other etiologies should be considered.

The approximate risk for appendicitis is <10%.

Observation at home with follow-up within 12–24 hours is appropriate for well appearing, stable patients with no barriers to follow-up (e.g., transportation). Must ensure follow-up.

Aim: To standardize the management of children with appendicitis.

NOTES: [see page 6, 7](#)




EXCLUSION GUIDELINES
Patients **excluded** from this guideline:

- Uncertain diagnosis
- ICU admission/severe illness
- Significant comorbidities
- Immunocompromised state
- Recent hospitalization
- Previous history of appendicitis [\(Note 9\)](#)

Aim: To standardize the management of children with appendicitis.


NOTES: [see page 6, 7](#)



PHM = Pediatric Hospital Medicine

Aim: To standardize the management of children with appendicitis.

NOTES: [see page 6, 7](#)




EXCLUSION GUIDELINES

Patients **excluded** from this guideline:

- Uncertain diagnosis
- ICU admission/severe illness
- Significant comorbidities
- Immunocompromised state
- Recent hospitalization
- Previous history of appendicitis (Note 9)

Aim: To standardize the management of children with appendicitis.



Communication:

- It is expected that the ED will communicate with Gen Surg on all appendicitis patients and that they will directly communicate with the PHM service on patients being admitted with PHM involvement.

Direct Admissions:

- If a patient is being directly admitted from an outside facility – PHM will be the primary service with Gen Surg co-managing.

Documentation:

- ED note is sufficient for H&P prior to the OR
- Non-perforated appendicitis patients will transition to Outpatient-in-a-Bed status (OPIB) post-operatively. Narrative summaries are not required on discharge for patients in OPIB status.
- PHM should document and bill commensurate with their level of involvement when non-perforated/OPIB status.

PHM = Pediatric Hospital Medicine

NOTE 1

- Surgery is important to prevent recurrence but is not the primary treatment for appendicitis.
- Previous studies have found that after initiation of antibiotics, there was no difference in outcomes (including likelihood of perforation) in patients who had surgery shortly after arrival to the hospital vs. up to 24 hours after arrival.

NOTE 2 – DISCHARGE CRITERIA

- Afebrile (x 24 hours if perforated)
- Completed at least 3 days (72 hours) of antibiotics post-op (if perforated)
- Pain controlled on oral analgesics
- Diarrhea is improving (if present)
- Tolerating PO intake
- Caregiver/child feel comfortable with discharge

Discharge instructions:

- Okay to bathe/shower 2 days after surgery
- Okay to swim 5 days after surgery
- No other activity restrictions (may limit gym/ sports for 2 weeks if family preference)
- Regular diet
- Follow-up with surgery in 2–4 weeks as needed

NOTE 3

- **Start TPN** when patient has been NPO for a total of seven days (including days prior to presentation)
- Consider initiation earlier in younger children, particularly if concern for decreased nutritional reserves

NOTE 4- Drain Removal

- Drain to be managed and followed by general surgery and IR. Removal will be at the discretion of the surgical service and IR based on clinical course and any additional imaging.

NOTE 5– Discharge planning for home antibiotics

- General Surgery team to order home IV antibiotics, PICC line supplies and cares, and outpatient labs (unless specifically communicated to the Hospital Medicine Team).
- Follow-up lab and evaluation can be done in the General Surgery clinic as an outpatient or through a patient’s PCP office.

NOTE 6– Non-operative Management of Non-perforated Appendicitis

- Instances in which operative management may be contraindicated include:
 - Hemodynamic instability
 - Co-occurring disease states such as respiratory infections/pneumonia
 - Concern for inflammatory bowel disease (Ulcerative colitis, Crohn’s disease)
- There may be rare instances of parental refusal of surgery
- In these instances, patients will be managed off guideline and with close surgical collaboration.
- Suggested management:
 - Admission, IV fluids, IV antibiotics for minimum of 24 hours, NPO for minimum of 12 hours and until improving
 - If no improvement within 24 hours then consider surgical management
 - If after IV antibiotics administered and 12 hour NPO status, may have clear liquid diet and advance if tolerated if all of the following criteria are met:
 - Decreased tenderness compared to presentation
 - Decreased pain compared to presentation
 - Resolution of nausea if present on admission
 - Decreased temperature/afebrile if fever present on or prior to admission
 - May transition to oral/PO antibiotics (first line: ciprofloxacin/metronidazole; second line: amoxicillin-clavulanate) once tolerating regular diet
 - Consider probiotics and/or yogurt supplementation
 - Discharge home to complete total course of 7 days of antibiotics once discharge criteria met
 - Completion of minimum of 24 hours of IV antibiotics
 - Completion of minimum of 24 hours of inpatient observation
 - Tolerating regular diet and at least one dose of oral antibiotics
 - Absence of abdominal pain
 - Afebrile
 - Agreement of any other consulting services (ex. GI)

NOTE 7– Considerations for ID consultation

Consider formal consultation with the Infectious Disease service in the following patient populations:

- Severe illness or immunocompromise
- History of recent hospitalization
- History of recent appendicitis – Patients presenting after initial management with concern for complication
- Persistent fever and/or lab abnormalities after 3 days despite adequate source control (if appropriate) and appropriate empiric antibiotic coverage

NOTE 8– Monitoring for adverse drug reactions

For patients on IV antibiotics for 7 days, it is recommended to obtain the following to monitor for potential adverse drug reactions. If signs of reaction, recommend discussion with pharmacy and/or ID.

- CBC with differential
- Hepatic panel with GGT
- Creatinine

NOTE 9– Patients returning after initial management of appendicitis with concern for complication

- These patients should not be managed on this guideline, but with close surgical consultation and strong consideration for Infectious Disease consultation.
- If patients are presenting within the first 4 weeks following initial management, it may be appropriate to re-initiate empiric antimicrobial therapy with ceftriaxone and metronidazole utilizing Q24H dosing regimens. This decision should be made in conjunction with the surgical service and potentially the ID service.
- For patients presenting greater than 4 weeks after initial intervention, ID should be consulted in conjunction with general surgery.

Common Medications in the Management of Appendicitis

Antibiotics	Ceftriaxone	50 mg/kg IV Q24H – max dose 2,000 mg	Peer reviewed data does support the use of once daily administration of ceftriaxone and metronidazole in the treatment of appendicitis and complicated appendicitis (rupture, abscess).
	Metronidazole	30 mg/kg IV Q24H – max dose 1,500 mg	
		10 mg/kg PO Q8H – max dose 500 mg	For off-guideline reference – there may be indications to transition to oral therapy in consultation with ID
	Ciprofloxacin	10 mg/kg IV Q12H – max dose 400 mg	For use in place of ceftriaxone if beta-lactam allergy
		15 mg/kg PO Q12H – max dose 500 mg	For off-guideline reference – there may be indications for transition to oral therapy in consultation with ID
Amoxicillin-clavulanic acid	22.5 mg/kg PO BID – max dose of 875 mg (Use a 7:1 formulation. If liquid, use 200-28.5 mg/5 mL, 400-57 mg/5 mL suspension)	For off-guideline reference - Second line after ciprofloxacin/metronidazole. Data supports the use of amox-clav in the management of some appendicitis and associated infections, particularly after a period of broad-spectrum IV antibiotic therapy	
Pain medications	Acetaminophen	15 mg/kg PO, PR, or IV Q6H scheduled or PRN – max of 75 mg/kg/day (or 4,000 mg/day – whichever is less)	
	Ibuprofen	10 mg/kg PO Q6H PRN – max of 40 mg/kg/day (or 2,400 mg/day – whichever is less)	
	Ketorolac	0.5 mg/kg/dose IV Q6H PRN – max of 15 mg/dose	Not to exceed 5 days of treatment
	Morphine	0.05-0.1 mg/kg/dose IV Q2-4H PRN	When using opioids, ensure Naloxone 10 mcg/kg IV Q2-3min PRN is available Consider early initiation of a bowel regimen post-operatively Patients managed for appendicitis typically do not require opioids once meeting discharge criteria.
	Hydromorphone	15 mcg/kg/dose (or 0.015 mg/kg/dose) Q2-4H PRN	
	Oxycodone	0.1-0.2 mg/kg/dose PO Q4-6H PRN	
Nausea medications	Ondansetron	0.15 mg/kg/dose IV/PO Q6H PRN – max of 8 mg/dose	

Disclaimer: This guideline is designed for general use with most patients; each clinician should use their own independent judgment to meet the needs of each individual patient. This guideline is not a substitute for professional medical advice, diagnosis or treatment.

REFERENCES

1. Cameron DB, Williams R, Geng Y, Gosain A, Arnold MA, Guner YS, Blakely ML, Downard CD, Goldin AB, Grabowski J, Lal DR, Dasgupta R, Baird R, Gates RL, Shelton J, Jancelewicz T, Rangel SJ, Austin MT. Time to appendectomy for acute appendicitis: A systematic review. *J Pediatr Surg*. 2018 Mar;53(3):396-405. doi: 10.1016/j.jpedsurg.2017.11.042. Epub 2017 Nov 20. PMID: 29241958.
2. Almström M, Svensson JF, Patkova B, Svenningsson A, Wester T. In-hospital Surgical Delay Does Not Increase the Risk for Perforated Appendicitis in Children: A Single-center Retrospective Cohort Study. *Ann Surg*. 2017 Mar;265(3):616-621. doi: 10.1097/SLA.0000000000001694. PMID: 28169930.
3. Gurien LA, Wyrick DL, Smith SD, Dassinger MS. Optimal timing of appendectomy in the pediatric population. *J Surg Res*. 2016 May 1;202(1):126-31. doi: 10.1016/j.jss.2015.12.045. Epub 2015 Dec 30. PMID: 27083958.
4. Becker C, Kharbanda A. Acute appendicitis in pediatric patients: an evidence-based review. *Pediatr Emerg Med Pract*. 2019 Sep;16(9):1-20. Epub 2019 Sep 2. PMID: 31461613.
5. Kharbanda AB, et al. Clinical Research on Emergency Services and Treatments Network (CREST) and the Critical Care Research Center, HealthPartners Institute. Effect of Clinical Decision Support on Diagnostic Imaging for Pediatric Appendicitis: A Cluster Randomized Trial. *JAMA Netw Open*. 2021 Feb 1;4(2):e2036344. doi: 10.1001/jamanetworkopen.2020.36344. PMID: 33560426; PMCID: PMC7873779.
6. Becker CR, Bergmann KR, Vazquez-Benitez G, Bretscher BM, Kharbanda AB. Resource utilization and outcomes among children risk stratified by pediatric appendicitis risk calculator at a tertiary pediatric center. *Acad Emerg Med*. 2022 Apr;29(4):415-422. doi: 10.1111/acem.14433. Epub 2022 Jan 12. PMID: 34942048.
7. Kharbanda AB, Vazquez-Benitez G, Ballard DW, Vinson DR, Chettipally UK, Kene MV, Dehmer SP, Bachur RG, Dayan PS, Kuppermann N, O'Connor PJ, Kharbanda EO. Development and Validation of a Novel Pediatric Appendicitis Risk Calculator (pARC). *Pediatrics*. 2018 Apr;141(4):e20172699. doi: 10.1542/peds.2017-2699. Epub 2018 Mar 13. PMID: 29535251; PMCID: PMC5869337.
8. Cotton DM, Vinson DR, Vazquez-Benitez G, Margaret Warton E, Reed ME, Chettipally UK, Kene MV, Lin JS, Mark DG, Sax DR, McLachlan ID, Rauchwerger AS, Simon LE, Kharbanda AB, Kharbanda EO, Ballard DW; Clinical Research on Emergency Services and Treatments (CREST) Network. Validation of the Pediatric Appendicitis Risk Calculator (pARC) in a Community Emergency Department Setting. *Ann Emerg Med*. 2019 Oct;74(4):471-480. doi: 10.1016/j.annemergmed.2019.04.023. Epub 2019 Jun 19. PMID: 31229394; PMCID: PMC8364751.
9. Ketha B, Stephenson KJ, Dassinger MS 3rd, Smith SD, Burford JM. Eliminating Use of Home Oral Antibiotics in Pediatric Complicated Appendicitis. *J Surg Res*. 2021 Jul;263:151-154. doi: 10.1016/j.jss.2020.12.059. Epub 2021 Feb 27. PMID: 33652177.
10. Maita S, Andersson B, Svensson JF, Wester T. Nonoperative treatment for nonperforated appendicitis in children: a systematic review and meta-analysis. *Pediatr Surg Int*. 2020 Mar;36(3):261-269. doi: 10.1007/s00383-019-04610-1. Epub 2019 Dec 14. PMID: 31838546; PMCID: PMC7012795.
11. Ingram MC, Harris CJ, Studer A, Martin S, Berman L, Alder A, Raval MV. Distilling the Key Elements of Pediatric Appendicitis Clinical Practice Guidelines. *J Surg Res*. 2021 Feb;258:105-112. doi: 10.1016/j.jss.2020.08.056. Epub 2020 Sep 30. PMID: 33010554; PMCID: PMC7736270.
12. Child J, Chen X, Mistry RD, et al. Pharmacokinetic and pharmacodynamic properties of metronidazole in pediatric patients with acute appendicitis: a prospective study. *J Pediatric Infect Dis Soc*. 2019;8(4):297-302. PMID 29788329
13. Hurst AL, Olson D, Somme S, et al. Once-daily ceftriaxone plus metronidazole versus ertapenem and/or cefoxitin for pediatric appendicitis. *J Pediatric Infect Dis Soc*. 2017;6(1):57-64. PMID 26703242.
14. St Peter SD, Tsao K, Spilde TL, et al. Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial. *J Pediatr Surg*. 2008;43(6):981-985. doi: 10.1016/j.jpedsurg.2008.02.018. PMID 18558169.

Workgroup: Short, Messbarger, Harrison, Ulman, Kharbanda. Previous workgroup members: Valusek